You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 22, 2024

Investigational Drug Information for Rimiducid


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Rimiducid?

Rimiducid is an investigational drug.

There have been 21 clinical trials for Rimiducid. The most recent clinical trial was a Phase 1 trial, which was initiated on December 27th 2018.

The most common disease conditions in clinical trials are Myelodysplastic Syndromes, Preleukemia, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are Bellicum Pharmaceuticals, Poseida Therapeutics, Inc., and National Cancer Institute (NCI).

There are seven US patents protecting this investigational drug and eighty-seven international patents.

Recent Clinical Trials for Rimiducid
TitleSponsorPhase
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid TumorsPoseida Therapeutics, Inc.Phase 1
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple MyelomaPoseida Therapeutics, Inc.Phase 1
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST TrialNational Cancer Institute (NCI)Phase 1

See all Rimiducid clinical trials

Clinical Trial Summary for Rimiducid

Top disease conditions for Rimiducid
Top clinical trial sponsors for Rimiducid

See all Rimiducid clinical trials

US Patents for Rimiducid

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
rimiducid ⤷  Sign Up Compositions and methods for treatment of cancer Aleta Biotherapeutics Inc. (Natick, MA) ⤷  Sign Up
rimiducid ⤷  Sign Up Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) ⤷  Sign Up
rimiducid ⤷  Sign Up Treatment of cancer using GFR .alpha.-4 chimeric antigen receptor THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Philadelphia, PA) NOVARTIS AG (Basel, CH) THE SCRIPPS RESEARCH INSTITUTE (La Jolla, CA) ⤷  Sign Up
rimiducid ⤷  Sign Up Treatment of cancer using a CD33 chimeric antigen receptor Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Rimiducid

Drugname Country Document Number Estimated Expiration Related US Patent
rimiducid Australia AU2016343809 2035-10-30 ⤷  Sign Up
rimiducid Brazil BR112018008326 2035-10-30 ⤷  Sign Up
rimiducid Canada CA3002674 2035-10-30 ⤷  Sign Up
rimiducid Chile CL2018001152 2035-10-30 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.